3Z: Zebrafish mutant model reveals novel drug candidates for ADHD
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology, 3Z...
FWD Group focuses on wellness for season three of its popular podcast series “Celebrate Living with FWD”
Season three airs today and brings together leading experts to explore all aspects of wellness: from mental and physical health through to financial wellness, social connectivity, purpose and meaning in life Seasons one and two established a global audience spanning 50 countries HONG KONG, Nov. 22, 2022 /PRNewswire/ -- FWD Group Holdings Limited ("FWD Group")...
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology
SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at the 45th San Antonio Breast Cancer Symposium (SABCS 2022) from 6-10 December 2022. Breast cancer is the most common malignant cancer...
First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM). TLX101 (4-L- iodo-phenylalanine,...
Quantivly exhibits at RSNA 2022 with AI-driven software to transform the way radiology leaders manage operations and increase access to imaging for the population.
Company's vision is to develop a "digital twin" for radiology facilities to allow monitoring, simulation, and optimization of operations with software before implementation in the real world. SOMERVILLE, Mass., Nov. 21, 2022 /PRNewswire/ -- Quantivly is highlighting new advances in its artificial intelligence (AI)-driven software for improving efficiency in medical imaging at the Radiological Society of North America (RSNA)...
IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical trials First...
United Imaging Drives Forward Several Major Innovations in Multiple Imaging Modalities
The company's IPO and 20,000th global installation are followed by new technological innovations, in keeping with its commitments to the U.S. and other markets. HOUSTON, Nov. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced a series of commercially available and 510k pending technologies. In its 11th year, United...
Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs
NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that four abstracts highlighting CFI-402257 and CFI-400945, the Company's potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022 at...
Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified
Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global provider of AI-powered cancer solutions, today...
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
Collaboration will bring together Umoja's iCIL platform and IASO's chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indications that are significantly underserved by today's standards of care. SEATTLE, SAN JOSE, Calif., SHANGHAI and NANJING, China, Nov. 21, 2022 /PRNewswire/ -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics...
